These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
295 related articles for article (PubMed ID: 30458989)
1. The interacting domains in cereblon differentially modulate the immunomodulatory drug-mediated ubiquitination and degradation of its binding partners. Tao J; Yang J; Xu G Biochem Biophys Res Commun; 2018 Dec; 507(1-4):443-449. PubMed ID: 30458989 [TBL] [Abstract][Full Text] [Related]
2. Immunomodulatory agents lenalidomide and pomalidomide co-stimulate T cells by inducing degradation of T cell repressors Ikaros and Aiolos via modulation of the E3 ubiquitin ligase complex CRL4(CRBN.). Gandhi AK; Kang J; Havens CG; Conklin T; Ning Y; Wu L; Ito T; Ando H; Waldman MF; Thakurta A; Klippel A; Handa H; Daniel TO; Schafer PH; Chopra R Br J Haematol; 2014 Mar; 164(6):811-21. PubMed ID: 24328678 [TBL] [Abstract][Full Text] [Related]
3. Structural basis of lenalidomide-induced CK1α degradation by the CRL4(CRBN) ubiquitin ligase. Petzold G; Fischer ES; Thomä NH Nature; 2016 Apr; 532(7597):127-30. PubMed ID: 26909574 [TBL] [Abstract][Full Text] [Related]
4. A genome-scale CRISPR-Cas9 screening in myeloma cells identifies regulators of immunomodulatory drug sensitivity. Liu J; Song T; Zhou W; Xing L; Wang S; Ho M; Peng Z; Tai YT; Hideshima T; Anderson KC; Cang Y Leukemia; 2019 Jan; 33(1):171-180. PubMed ID: 30026574 [TBL] [Abstract][Full Text] [Related]
5. Homo-PROTACs for the Chemical Knockdown of Cereblon. Steinebach C; Lindner S; Udeshi ND; Mani DC; Kehm H; Köpff S; Carr SA; Gütschow M; Krönke J ACS Chem Biol; 2018 Sep; 13(9):2771-2782. PubMed ID: 30118587 [TBL] [Abstract][Full Text] [Related]
6. Structure of the DDB1-CRBN E3 ubiquitin ligase in complex with thalidomide. Fischer ES; Böhm K; Lydeard JR; Yang H; Stadler MB; Cavadini S; Nagel J; Serluca F; Acker V; Lingaraju GM; Tichkule RB; Schebesta M; Forrester WC; Schirle M; Hassiepen U; Ottl J; Hild M; Beckwith RE; Harper JW; Jenkins JL; Thomä NH Nature; 2014 Aug; 512(7512):49-53. PubMed ID: 25043012 [TBL] [Abstract][Full Text] [Related]
7. A novel effect of thalidomide and its analogs: suppression of cereblon ubiquitination enhances ubiquitin ligase function. Liu Y; Huang X; He X; Zhou Y; Jiang X; Chen-Kiang S; Jaffrey SR; Xu G FASEB J; 2015 Dec; 29(12):4829-39. PubMed ID: 26231201 [TBL] [Abstract][Full Text] [Related]
8. [Recent topics in IMiDs and cereblon]. Ito T; Handa H Rinsho Ketsueki; 2017; 58(10):2067-2073. PubMed ID: 28978850 [TBL] [Abstract][Full Text] [Related]
9. Targeting cereblon in hematologic malignancies. Fuchs O Blood Rev; 2023 Jan; 57():100994. PubMed ID: 35933246 [TBL] [Abstract][Full Text] [Related]
10. Humanized cereblon mice revealed two distinct therapeutic pathways of immunomodulatory drugs. Gemechu Y; Millrine D; Hashimoto S; Prakash J; Sanchenkova K; Metwally H; Gyanu P; Kang S; Kishimoto T Proc Natl Acad Sci U S A; 2018 Nov; 115(46):11802-11807. PubMed ID: 30373817 [TBL] [Abstract][Full Text] [Related]
11. Generation of a lenalidomide-sensitive syngeneic murine in vivo multiple myeloma model by expression of Crbn Röhner L; Ng YLD; Scheffold A; Lindner S; Köpff S; Brandl A; Beilhack A; Krönke J Exp Hematol; 2021 Jan; 93():61-69.e4. PubMed ID: 33186626 [TBL] [Abstract][Full Text] [Related]
12. Defining the human C2H2 zinc finger degrome targeted by thalidomide analogs through CRBN. Sievers QL; Petzold G; Bunker RD; Renneville A; Słabicki M; Liddicoat BJ; Abdulrahman W; Mikkelsen T; Ebert BL; Thomä NH Science; 2018 Nov; 362(6414):. PubMed ID: 30385546 [TBL] [Abstract][Full Text] [Related]
13. Cereblon suppresses the lipopolysaccharide-induced inflammatory response by promoting the ubiquitination and degradation of c-Jun. Yang J; Huang M; Zhou L; He X; Jiang X; Zhang Y; Xu G J Biol Chem; 2018 Jun; 293(26):10141-10157. PubMed ID: 29748389 [TBL] [Abstract][Full Text] [Related]
14. A novel cereblon modulator recruits GSPT1 to the CRL4(CRBN) ubiquitin ligase. Matyskiela ME; Lu G; Ito T; Pagarigan B; Lu CC; Miller K; Fang W; Wang NY; Nguyen D; Houston J; Carmel G; Tran T; Riley M; Nosaka L; Lander GC; Gaidarova S; Xu S; Ruchelman AL; Handa H; Carmichael J; Daniel TO; Cathers BE; Lopez-Girona A; Chamberlain PP Nature; 2016 Jul; 535(7611):252-7. PubMed ID: 27338790 [TBL] [Abstract][Full Text] [Related]
15. UBE2G1 governs the destruction of cereblon neomorphic substrates. Lu G; Weng S; Matyskiela M; Zheng X; Fang W; Wood S; Surka C; Mizukoshi R; Lu CC; Mendy D; Jang IS; Wang K; Marella M; Couto S; Cathers B; Carmichael J; Chamberlain P; Rolfe M Elife; 2018 Sep; 7():. PubMed ID: 30234487 [TBL] [Abstract][Full Text] [Related]
16. Glutamine Triggers Acetylation-Dependent Degradation of Glutamine Synthetase via the Thalidomide Receptor Cereblon. Nguyen TV; Lee JE; Sweredoski MJ; Yang SJ; Jeon SJ; Harrison JS; Yim JH; Lee SG; Handa H; Kuhlman B; Jeong JS; Reitsma JM; Park CS; Hess S; Deshaies RJ Mol Cell; 2016 Mar; 61(6):809-20. PubMed ID: 26990986 [TBL] [Abstract][Full Text] [Related]
17. [Thalidomide, cereblon and multiple myeloma]. Ogura T Nihon Rinsho; 2015 Jan; 73(1):149-55. PubMed ID: 25626321 [TBL] [Abstract][Full Text] [Related]
18. USP15 antagonizes CRL4 Nguyen TV Proc Natl Acad Sci U S A; 2021 Oct; 118(40):. PubMed ID: 34583995 [TBL] [Abstract][Full Text] [Related]
19. A Cereblon Modulator (CC-220) with Improved Degradation of Ikaros and Aiolos. Matyskiela ME; Zhang W; Man HW; Muller G; Khambatta G; Baculi F; Hickman M; LeBrun L; Pagarigan B; Carmel G; Lu CC; Lu G; Riley M; Satoh Y; Schafer P; Daniel TO; Carmichael J; Cathers BE; Chamberlain PP J Med Chem; 2018 Jan; 61(2):535-542. PubMed ID: 28425720 [TBL] [Abstract][Full Text] [Related]
20. [Cereblon as a primary target of IMiDs]. Ito T; Handa H Rinsho Ketsueki; 2019; 60(9):1013-1019. PubMed ID: 31597822 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]